SCHEMBL5448804

SCHEMBL5448804

COc1ccc(Cc2ccc(S(=O)(=O)c3cc4c(cc3N(C)C)CCN(C)CC4)cc2)cc1C#N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.37
KCNH2 Q12809 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GALR3 O60755 1/20 0.36
NR2F2 P24468 1/20 0.36
RAB9A P51151 1/20 0.36
HTR6 P50406 3/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
DRD3 P35462 1/20 0.36
S1PR1 P21453 10/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
LTA4H P09960 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450652 0.87 USP2 (0.36) KCNH2MEN1KMT2AHTR6DRD2
SCHEMBL5455500 0.87 KCNJ1 (0.38) KCNJ1KCNH2HTR6DRD2HTR2A
SCHEMBL5458561 0.85 HTR6 (0.45) KCNJ1KCNH2HTR6DRD2HTR2A
SCHEMBL5459209 0.84 DRD1 (0.43) DRD2HTR2AHTR2CDRD3ALDH1A1
SCHEMBL5450383 0.83 UTS2R (0.38) GALR3NR2F2RAB9AHTR6DRD2
SCHEMBL5450675 0.83 KCNH2 (0.39) KCNJ1KCNH2HTR6DRD2HTR2A
SCHEMBL5448126 0.82 LTA4H (0.47) MEN1KMT2ADRD2DRD3ALDH1A1
SCHEMBL5458510 0.82 HTR6 (0.36) KCNJ1KCNH2MEN1KMT2AHTR6
SCHEMBL5450670 0.82 SIGMAR1 (0.40) KCNH2GALR3NR2F2RAB9AHTR6
SCHEMBL5452773 0.81 USP2 (0.42) KCNJ1KCNH2HTR6DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 KCNJ1 348/4885KCNH2 278/4885MEN1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.